Escolar Documentos
Profissional Documentos
Cultura Documentos
Priscila de Nazar Quaresma PINHEIRO, Jacqueline Silva do Rosrio PENICHE , Taysa Ribeiro
SCHALCHE4, Michelli rica Souza FERREIRA5e Anny do Rosrio Ferreira CAMPOS6
RESUMO
Objetivo: conhecer as caractersticas farmacolgicas do antimalrico Lumefantrina, o qual est
sendo utilizado na malaria falciparum resistente aos antigos tratamentos, tal como: estrutura
qumica e propriedades fisico-qumicas, farmacocintica, mecanismo de ao entre outros, pois
atravs delas pode-se observar se o frmaco bem tolerado, seguro e eficaz. Esta reviso
objetiva ampliar e incentivar os conhecimentos sobre os aspectos farmacolgicos da
lumefantrina, servindo como apoio para futuros estudos sobre este frmaco. Mtodo: foi
realizada uma pesquisa na literatura sobre as caractersticas farmacolgicas desse frmaco.
Consideraes finais: pode-se observar que a lumefantrina bem tolerada, de ao rpida e
eficaz em crianas e adultos.
Efeitos adversos
SUMMARY
PHARMACOLOGICAL ASPECTS OF ANTIMALARIAL LUMEFANTRINE
Priscila de Nazar Quaresma PINHEIRO, Jacqueline Silva do Rosrio PENICHE, Taysa Ribeiro
SCHALCHE, Michelli rica Souza FERREIRA e Anny do Rosrio Ferreira CAMPOS
REFERNCIAS
1. Alrajhi, A; Frayha, HH. Cloroquine-Resistant Plasmodium Falciparum: Is it our turn? Ann. Saud.
Med. 1997, 17( 2): 151-155
4. Jornal Gazeta Mercantil. Washington - 02 de dezembro de 2008 (Caderno C - Pg. 8). Disponvel em
http://www.abiquif.org.br/noticias/clipping/02_12_08_FDA.html. Acessado em 23 de dezembro de 2008.
5. Csar, IC; Nogueira, FHA; Pianetti, GA. Simultaneous determination of artemether and lumefantrine
in fixed dose combination tablets by HPLC with UV detection. J. Pharmaceut. Biomed. Anal. 2008, 48
(3): 951-954
7. Go, M; Li, Q. Interaction of the antimalarial agents halofantrina and lumefantrina with lipid bilayers.
Chem. Pharmaceut. Bull. 2003, 51(3):241-246
8. Annerberg, A; Singtoroj, T; Tipmanee, P; White, NJ; Day, NPJ; Lindegardh, N. High throughput assay
for the determination of lumefantrine in plasma. J. chromatogr. B. 2005, 822 (1-2): 330-333
9. Wernsdorfer, WH; Landgraf, B; Kilimali, VAEB; wernsdorfer, G. Activity of benflumetol and its
enantiomers in fresh isolates of Plasmodium falciparum from East Africa. Acta trop. 1998, 70(1): 9-15
10. Zeng, M; Lu, Z; Yang, S; Zhang, M; Liao, J; Liu, S. et al. Determination of benflumetol in human
plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. J.
chromatogr. B: Biomed. Appl. 1996, v. 681(2):299-306
12. Bindshedler, M; Degen, P; Lu, ZL. Comparative bioavailability of benflumetol after administration
of single oral doses of co-artemether under fed and fasted conditions to healthy subjects. International
Congress for Tropical Medicine and Malaria, 14, Nagasaki, 1996
13. Ezzet, F.; Van vugt, M.; Nosten, F.; Looareesuwan, S.; White, N.J. Pharmacokinetics and
Pharmacodynamics of Lumefantrine (Benflumetol) in Acute falciparum malria. Antim. Agents
Chemother. 2000, 44(3):697-704
14. White, NJ; Van vugt, M; Ezzet, F. Clinical pharmacokinetics and pharmacodynamics of artemether-
lumefantrine. Clin. Pharmacokinet. 1999, 37(2):105-125
15. Ashley, EA; Stepniewska, K; Lindegardh, N; Mcgready ,R; Annerberg, A; Hutagalung, R. et al.
Pharmacokinetic study of artemether-lumefantrina given once daily for the treatment of uncomplicated
multidrug-resistant falciparum malaria. Trop. Med. Intern. Health, 2007,12 (2):201-208
16. Colussi, D; Parisot, C; Legay, F; Lefvre, G. Binding of artemether and lumefantrine to plasma
proteins and erythrocytes. Eur. j. Pharmac. science. 1999, 9 (1): 9-16
17. Mansor, SM; Navaratnam, V; Yahaya, N; Nair, NK; Wernsdorfer, WH; Degen, PH. Determination of
a new antimalarial drug, benflumetol, in blood plasma by high-performance liquid chromatography. J.
Chromatogr. B, 1996, 682 (2):321-325
19. Novartis Pharmaceutical Ltd. The electronic Medicines Compendium: Riamet, 2008. Disponvel em
http://emc.medicines.org.uk/medicine/9196/SPC/Riamet+20+120mg+tablets. Acessado em 09 de maro
de 2009.
20. Ntale, M; Beck, O; Ogwal-okeng, JW; Mahindi, M; Gustafsson, LL. A field-adapted sampling and
HPLC quantification method for lumefantrine and its desbutyl metabolite in whole blood spotted on filter
paper. J. Chromatogr. B, 2008, 876(2):261265
21. Djimd, A; Lefvre, G. Understanding the pharmacokinetics of Coartem. Malar. J. 2009, 8(1): 1-8
22. Checchi, F; Piola, P; Fogg, P; Bajunirwe, F; Biraro, S; Grandesso, F. et al. Supervised versus
unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetics and
dosage-related findings from a clinical trial in Uganda. Malar. J. 2006, 5(59): 1-8
23. Bakshi, R; Hermeling-fritz, I; Gathmann, I; Alteri, E; An integrated assessment of the clinical safety
of artemether-lumefantrine:a new oral fixed-dose combination antimalarial drug. Trans. R. Soc. Trop.
Med. hyg. 2000, 94 (4): 419-424
24. Valecha, N; Srivastava, P; Mohanty, SS; Mittra, P; Sharma, SK; Tyagi, PK. et al. Therapeutic efficacy
of artemether-lumefantrine in uncomplicated falciparum malaria in ndia. Malar. J. 2009, 8(107): 1-8
25. Katrak, S; Gasasira, A; Arinaitwe, E; Kakuru, A; Wanzira, H; Bigira, V. et al. Safety and tolerability
of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and
uninfected children. Malar. J., 2009, 8( 272): 1-8
26. Toovey, S; Jamieson, A. Audiometric changes associated with the treatment of uncomplicated
falciparum malaria with co-artemether. Trans. R. Soc. Trop. Med. Hyg. 2004, 98 (5):261-267
27. Olufemi, MA; Gabriel, O; Sheriff, O; Oladele, AA. Effects of Short Term Administration of
Artemether Lumefantrine on Testicular Functions and Antioxidant Defence in the Rat. Res. J. Medicine
Med. Sci. 2009, 4(2):165-170
30. German, P; Parikh, S; Lawrence, J; Dorsey, G; Rosenthal, P; Havlir ,D. et al. Lopinavir/ritonavir
affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J.
Acq. Imm. Def. Synd.. 2009, 51(4): 424-429.